International Conference, AstraZeneca presented results on its interleukin-33 (IL-33) inhibitor, tozorakimab, from its ...

FEV 1, COPDCompEx event risk and mucus plugging possibly improve with receipt of anti-IL-33 monoclonal antibody tozorakimab. Some patient subgroups achieved more benefits in lung function with ...

AstraZeneca executives say they are “not worried” that the failure of tozorakimab in a phase 2 chronic obstructive pulmonary disease (COPD) trial will throw their plans for the anti-IL-33 ...

The drugmaker moved tozorakimab, an anti-IL-33 monoclonal antibody, into phase 2b in DKD in 2019 in response to evidence that inflammation plays a role in disease. Biomarkers of inflammation ...

AstraZeneca progressed tozorakimab into Phase IIb for DKD in 2019, as there was evidence that increased inflammation is associated with deterioration in renal function. In addition, the trial ...

On 18 May at the 2025 American Thoracic Society (ATS) International Conference, AstraZeneca presented results on its interleukin-33 (IL-33) inhibitor, tozorakimab, from its FRONTIER programmes ...